NALIRIFOX Dose Reductions Maintain Efficacy in Pancreatic Cancer
Key Takeaways from the NAPOLI 3 Trial (Based on the Provided Text)
Hear’s a breakdown of the key takeaways from the provided text regarding the NAPOLI 3 trial and the NALIRIFOX regimen:
Efficacy & Comparison to Other Regimens:
18-Month Survival: 18-month survival with NALIRIFOX was 18%, but the speaker cautions against direct comparison to other trials due to differences in patient populations and “curve flattening.”
Median OS Similar: The median overall survival (OS) appears to be similar to other regimens, despite the 18-month survival data.
ORR: NALIRIFOX showed an Objective Response Rate (ORR) of 41.8%, compared to 30% for FOLFIRINOX and 36.2% for gemcitabine/nab-paclitaxel. The speaker believes this difference might potentially be due to a different patient population.
Stable Disease Rate: The stable disease rate was consistent between NALIRIFOX (26%) and gemcitabine/nab-paclitaxel (26%).
CA 19-9 Levels: Unlike gemcitabine/nab-paclitaxel (where normal CA 19-9 patients didn’t benefit), both FOLFIRINOX and NALIRIFOX showed benefit regardless of CA 19-9 levels. Benefit was also seen regardless of metastasis site, age, or sex. Not Necessarily More Potent: The speaker doesn’t conclude NALIRIFOX is more potent than other regimens based on this data.
Tolerability & Adverse Events (AEs):
Similar Toxicity Profile: NALIRIFOX’s grade 3+ AEs (86%), dose reduction rates, discontinuation rates, and treatment-related deaths (6%) were remarkably similar to gemcitabine/nab-paclitaxel (87%, same rates, 6%). This suggests it’s not necessarily less toxic than FOLFIRINOX.
Specific AEs:
Diarrhea: More common with NALIRIFOX (20%) than gemcitabine/nab-paclitaxel (5%).
Neutropenia & Anemia: Lower rates of neutropenia (14% vs 25%) and anemia (11% vs 17%) were observed with NALIRIFOX compared to gemcitabine/nab-paclitaxel.
Dose Reduction:
Dose Reduction is Beneficial: Surprisingly, patients who required dose reductions of the liposomal irinotecan component of NALIRIFOX actually had better median OS (12.6 months) than those who didn’t (9.4 months).
Restarting at Same Dose: the speaker suggests avoiding dose delays and restarting at the same dose.
Overall Impression:
The speaker emphasizes caution when comparing NALIRIFOX to other regimens. While the ORR is promising, the tolerability profile appears similar to existing treatments, and the key finding is that dose reduction doesn’t necessarily negate benefit – in fact, it may be associated with improved outcomes. Further research is needed to determine if NALIRIFOX is truly more tolerable or potent.